Introduction: Takayasu arteritis (TA) is a rare, large vessel vasculitis, which is characterized by substantial morbidity and premature mortality. Several approaches have been used in the recent years for the management of the disease, with some promising results. The best therapeutic strategies still need to be identified. Areas covered: This article discusses the main clinical features of TA and the recent insights into diagnosis and treatments. A search has been undertaken on PubMed and Scopus databases and the most relevant references have been considered. Expert opinion: The identification of the most effective regimens able to control TA unrelenting vascular inflammation without undue toxicity remains a challenge. To define the validated biomarkers and the activity criteria reflecting the specific features of vascular inflammation, and possibly predicting its outcome, represents a critical challenge for physicians in the next years. © 2013 Informa UK, Ltd.

Management options for Takayasu arteritis / Tombetti, E., Manfredi, A., Sabbadini, M.G., Baldissera, E.. - In: EXPERT OPINION ON ORPHAN DRUGS. - ISSN 2167-8707. - 1:9(2013), pp. 685-693. [10.1517/21678707.2013.827570]

Management options for Takayasu arteritis

Tombetti E.;Manfredi A.;Sabbadini M. G.;
2013-01-01

Abstract

Introduction: Takayasu arteritis (TA) is a rare, large vessel vasculitis, which is characterized by substantial morbidity and premature mortality. Several approaches have been used in the recent years for the management of the disease, with some promising results. The best therapeutic strategies still need to be identified. Areas covered: This article discusses the main clinical features of TA and the recent insights into diagnosis and treatments. A search has been undertaken on PubMed and Scopus databases and the most relevant references have been considered. Expert opinion: The identification of the most effective regimens able to control TA unrelenting vascular inflammation without undue toxicity remains a challenge. To define the validated biomarkers and the activity criteria reflecting the specific features of vascular inflammation, and possibly predicting its outcome, represents a critical challenge for physicians in the next years. © 2013 Informa UK, Ltd.
2013
Inglese
Informa Healthcare
1
9
685
693
9
Pubblicato
Esperti anonimi
Internazionale
Goal 3: Good health and well-being
Angioplasty
Medical therapy
Surgery
Takayasu arteritis
TNF inhibitors
No
Management options for Takayasu arteritis / Tombetti, E., Manfredi, A., Sabbadini, M.G., Baldissera, E.. - In: EXPERT OPINION ON ORPHAN DRUGS. - ISSN 2167-8707. - 1:9(2013), pp. 685-693. [10.1517/21678707.2013.827570]
none
4
info:eu-repo/semantics/article
262
Tombetti, E.; Manfredi, A.; Sabbadini, M. G.; Baldissera, E.
1 Contributo su Rivista::1.1.1 Articolo in rivista - Review
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/206264
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 15
social impact